


**CLAIMS**

1. A compound of Formula I including its stereoisomers, pharmaceutically  
 5 acceptable salts, and hydrates thereof,




I


where:

- X and Y are independently selected from halogen, hydroxymethyl, and  
 10 acetoxymethyl;

R<sup>1</sup> is selected from C<sub>1-6</sub>alkyl, C<sub>3-6</sub>alkenyl, C<sub>3-6</sub>alkynyl, C<sub>3-7</sub>cycloalkyl,

C<sub>5-7</sub>cycloalkenyl, -(CH<sub>2</sub>)<sub>1-6</sub>CO<sub>2</sub>R<sup>3</sup>, and -(CH<sub>2</sub>)<sub>n</sub>-; ;

R<sup>2</sup> is selected from hydrogen, C<sub>1-6</sub>alkylcarbonyl, C<sub>3-7</sub>cycloalkylcarbonyl, CONHR<sup>3</sup>,



- 15 R<sup>3</sup> is selected from hydrogen and C<sub>1-6</sub>alkyl;  
 R<sup>4</sup>, R<sup>5</sup>, and R<sup>6</sup> are independently selected from hydrogen, C<sub>1-6</sub>alkyl, and C<sub>1-6</sub>alkoxy;  
 m is 0 or an integer from 1 to 6; and  
 n is 0 or an integer from 1 to 6.

- 20 2. A compound of claim 1 wherein R<sup>3</sup> is methyl, the carbon to which R<sup>3</sup> is  
 attached is of the (R) configuration, and m is 0.

3. A compound of claim 1 where  $R^1$  is  $C_{1-6}$ alkyl,  $C_{3-6}$ alkenyl, or  $C_{3-6}$ alkynyl.
4. A compound of claim 2 where  $R^1$  is  $C_{1-6}$ alkyl,  $C_{3-6}$ alkenyl, or  $C_{3-6}$ alkynyl.
5. A compound of claim 2 selected from the following group:
 

N-(2,5-dichlorophenyl)-N-(4-hydroxy-1-hexyn-5-yl)-4-chlorobenzenesulfonamide;

N-(2-fluoro-5-chlorophenyl)-N-(4-hydroxy-1-hexyn-5-yl)-4-chlorobenzenesulfonamide;

N-(2-fluoro-5-chlorophenyl)-N-(4-hydroxy-1-hexen-5-yl)-4-chlorobenzenesulfonamide;

N-(2-fluoro-5-chlorophenyl)-N-(3-hydroxyhex-2-yl)-4-chlorobenzenesulfonamide; and

N-(2-hydroxymethyl-5-chlorophenyl)-N-(2-(N-3-(1-imidazolyl)prop-1-yl-carbamoyl)but-3-yl)-4-chlorobenzenesulfonamide.
6. A compound of claim 1 wherein  $R^3$  is methyl, the carbon to which  $R^3$  is attached is of the (R) configuration, and m is 1.
7. A pharmaceutical composition for the treatment of disorders responsive to the inhibition of  $\beta$ -amyloid peptide production wherein the composition comprises a therapeutically effective amount of a compound of claim 1 in association with a pharmaceutically acceptable carrier or diluent.
8. A pharmaceutical composition of claim 7 suitable for oral administration.
9. A method for the treatment of disorders responsive to the inhibition of  $\beta$ -amyloid peptide production in a mammal in need thereof, which comprises administering to said mammal a therapeutically effective amount of a compound of claim 1.

10. A method of claim 9 wherein said disorder is Alzheimer's Disease and Down's Syndrome.